118
Participants
Start Date
March 9, 2023
Primary Completion Date
March 31, 2024
Study Completion Date
December 31, 2025
Serplulimab
Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
RECRUITING
Qilu Hospital of Shandong University, Jinan
Shandong University
OTHER